Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 69, n° 6S1
pages 27-35 (décembre 2013)
Doi : 10.1016/j.jaad.2013.04.043
accepted : 21 April 2013
Rosacea: Current state of epidemiology

Jerry Tan, MD a, , Mats Berg, MD b
a Department of Medicine, University of West Ontario, Windsor, Ontario, Canada 
b Division of Dermatology, University of Uppsala Academic Hospital, Uppsala, Sweden 

Reprint requests: Jerry Tan, MD, Department of Medicine, University of Western Ontario, 2224 Walker Rd, Suite 300, Windsor, Ontario, Canada N8W 5L7.

Case definitions are critical in epidemiologic research. However, modern disease indicators must now consider complex data from gene-based research along with traditional clinical parameters. Rosacea is a skin disorder with multiple signs and symptoms. In individuals, these features may be multiple or one may predominate. While studies on the epidemiology of rosacea have previously been sparse, there has been a recent increase in research activity. A broader body of epidemiological information that includes a greater variety of countries beyond Northern Europe and general population-based demographics is needed. As there are operational issues in current case definitions of rosacea subtypes—rationalization and standardization—universal consistent applications in future research is also imperative. Further improvement in disease definition combining new research information along with clinical pragmatism should increase the accuracy of rosacea case ascertainment and facilitate further epidemiological research.

The full text of this article is available in PDF format.

Key words : comorbidities, epidemiology, prevalence, risk factors, rosacea, subtype

Abbreviations used : CI, GST, NRSEC, OR, UV

 Publication of this article was supported by a grant from Galderma International. Editorial support provided by Galderma International.
 Disclosure: Dr Tan has served on an advisory board and as a consultant and speaker for Galderma and received grants and honoraria in compensation. Dr Berg has no conflicts of interest to declare.

© 2013  American Academy of Dermatology, Inc.@@#104156@@